GlucoTrack (GCTK) has issued an update.
Glucotrack, Inc. has announced the successful completion of a 60-day preclinical study on epidural glucose monitoring, showcasing a significant milestone for the company. The results, which may have positive implications for those tracking the company’s progress, are detailed in a recent press release. This development could interest investors as it demonstrates the company’s advancements in the field of glucose monitoring technology.
For a thorough assessment of GCTK stock, go to TipRanks’ Stock Analysis page.
